Inclusion Criteria:

- Written informed consent granted prior to initiation of any study-specific screening
procedures, given with the understanding that the patient has the right to withdraw
from the study at any time, without prejudice

- 18 year of age or older

- Histologically or cytologically confirmed locally advanced, inoperable or metastatic
primary solid tumors

- Measurable disease as defined by Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1

- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x upper limit of
normal (ULN) or ≤ 5 x ULN with metastatic liver disease

- Hemoglobin ≥ 10 g/dl (or ≥ 9 g/dl for expanded cohort)

- Total bilirubin ≤ 1.5 x ULN

- Serum creatinine ≤ 1.5 x ULN

- Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L

- Platelets ≥ 100 x 10^9/L

- Women of childbearing potential must have a negative pregnancy test performed within
seven days prior to the start of study drug

- Male and female subjects of child-bearing potential must agree to use double-barrier
contraceptive measures, oral contraception, or avoidance of intercourse during the
study and for 90 days after last investigational drug dose received

Exclusion Criteria:

- Other cancer within the last three years, with the exception of adequately treated
cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell
carcinoma of the skin

- Previous anti-cancer chemotherapy, radiotherapy, major surgery, immunotherapy or
investigational agents within 4 weeks prior to the first day of study defined
treatment

- History of cardiac disease: congestive heart failure defined as Class II to IV per
New York Heart Association (NYHA) classification; active coronary artery disease
(CAD); previously diagnosed bradycardia or other cardiac arrhythmia defined as ≥
Grade 2 according to National Cancer Institute (NCI)-Common Terminology Criteria for
Adverse Events (CTCAE) (version 3.0), or uncontrolled hypertension; myocardial
infarction occurred within 6 months prior to study entry (myocardial infarction
occurred > 6 months prior to study entry is permitted)

- Active clinically serious infections defined as ≥ Grade 2 according to NCI CTCAE,
version 3.0

- Substance abuse, medical, psychological or social conditions that may, in the opinion
of the Investigator, interfere with the patient's participation in the study or
evaluation of the study results

- Any condition that is unstable or which could jeopardize the safety of the patient
and his/her protocol compliance

- Known human immunodeficiency virus (HIV) infection

- Pregnancy or breast-feeding

- Inability to swallow oral medications

- Significant gastrointestinal disorder, in the opinion of the Investigator, could
interfere with the absorption of ARQ 197 and/or gemcitabine (e.g. significant,
uncontrolled inflammatory bowel disease or extensive small bowel resection)

- Central nervous system metastases